Hot Biotech Movers: Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals (NASDAQ:ACHN), MannKind Corp. (NASDAQ:MNKD), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

On 3 February, Gilead Sciences, Inc. (NASDAQ:GILD) announced its results of operations for the fourth quarter and full year 2014. Total revenues for the fourth quarter of 2014 were $7.3 billion compared to $3.1 billion for the fourth quarter of 2013.On Friday shares of Gilead Sciences Inc. (NASDAQ:GILD) closed at $97.48. Company’s sales growth for last 5 years was 16.00% and EPS growth for next 5 years is recorded as 33.42%.

Achillion Pharma (NASDAQ: ACHN) announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in last trading activity fell -2.35% to close at $10.82. Company weekly performance is -27.14% while its quarterly performance stands at 6.60%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is -35.86% away from its 52 week high.

On 3 February, Sanofi and MannKind Corporation (NASDAQ:MNKD) announced that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. On last trading day MannKind Corp. (NASDAQ:MNKD) fell -1.83% to close at $6.97. Its volatility for the week is 5.25% while volatility for the month is 5.17%. MNKD’s EPS growth for past 5 years was 26.50%. MannKind Corp. (NASDAQ:MNKD) monthly performance is 23.36%.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will present at the Leerink Global Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Thursday, February 12, at 3:30 p.m. (ET). Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has 0.90% insider ownership while its institutional ownership stands at 68.30%. In last trading activity company’s stock closed at $6.64.

Leave a Reply

Your email address will not be published.